CaRi-Heart technology’s advanced AI algorithms allows health specialists to obtain the coronary inflammation data from CCTA scans. Credit: National Cancer Institute on Unsplash.

Caristo Diagnostics has raised £13m ($16.3m) in a Series A financing round to advance its CaRi-Heart technology for cardiac disease detection into standards of cardiac care in major global markets.

Led by Oxford Science Enterprises, the financing round saw participation from many investors including Oxford Investment Consultants, BGF, Oxford University and Longwall Venture Partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CaRi-Heart is an artificial intelligence (AI)-assisted diagnostics and risk prediction tool, which is designed to support the diagnosis of coronary artery disease and offer an improved prediction of disease risk.

Using the company’s Fat Attenuation Index (FAI) technology, the advanced AI algorithms of the tool enable health specialists to obtain coronary inflammation measurements from cardiac computed tomography angiography (CCTA) scans.

The FAI Score determines the risk of cardiac mortality caused by coronary inflammation.

See Also:

In addition, CaRi-Heart technology also offers long-term cardiac mortality risk by combining coronary inflammation with standard clinic risk factors, as well as the coronary plaques’ presence.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Coinciding with the fundraising announcement, Caristo Diagnostics has welcomed Frank Cheng as its new CEO.

Frank Cheng said: “Caristo has been on an exciting journey since 2018 as the company turned a scientific idea into a validated clinical offering, protected our intellectual property, published impressive results in leading peer-reviewed medical journals and secured initial regulatory approvals.

“Our Series A fundraise will accelerate Caristo’s growth in our existing UK and EU markets, while we lay solid foundations for US market entry.”